SCHEMBL841601

SCHEMBL841601

CC(C)c1cc(Br)cc(C(C)C)c1C=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.52
GABRB1 P18505 1/20 0.52
ALB P02768 2/20 0.35
MCL1 Q07820 4/20 0.34
LMNA P02545 3/20 0.34
ALDH1A1 P00352 3/20 0.34
BCL2 P10415 3/20 0.34
KDM4E B2RXH2 2/20 0.34
MEN1 O00255 2/20 0.34
NPC1 O15118 2/20 0.34
USP2 O75604 2/20 0.34
POLB P06746 2/20 0.34
GAA P10253 2/20 0.34
MAPT P10636 2/20 0.34
THRB P10828 2/20 0.34
HPGD P15428 2/20 0.34
ALOX12 P18054 2/20 0.34
MAPK1 P28482 2/20 0.34
BLM P54132 2/20 0.34
KMT2A Q03164 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12030880 0.79 ALB (0.43) ALBMCL1LMNAALDH1A1BCL2
SCHEMBL2590567 0.79 FABP4 (0.52) GABRA1ALBMCL1LMNAALDH1A1
SCHEMBL6765852 0.75 GABRA1 (0.45) GABRA1GABRB1LMNAALDH1A1SMN1; SMN2
SCHEMBL841863 0.74 GABRA1 (0.48) GABRA1GABRB1
SCHEMBL7026756 0.74 ERN1 (0.47) LMNAALDH1A1KMT2AAKR1B1HTT
SCHEMBL10322298 0.74 GABRA1 (0.64) GABRA1GABRB1ALDH1A1ERN1TYR
SCHEMBL861863 0.72 GABRA1 (0.47) GABRA1GABRB1
SCHEMBL15264345 0.72 ERN1 (0.47) GABRA1GABRB1LMNAALDH1A1SMN1; SMN2
SCHEMBL841637 0.72 GABRA1 (0.47) GABRA1GABRB1
SCHEMBL20681258 0.72 GABRA1 (0.64) GABRA1GABRB1LMNAPOLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120019042-A Compounds for the treatment of neurodegenerative diseases 细胞基因公司 2025-05-16 CN disclosed
CN-117500785-A Azetidinyl-containing carboxylic acid compounds for the treatment of neurodegenerative diseases 细胞基因公司 2024-02-02 CN disclosed
EP-3569606-B1 METAL COMPLEXES OF CYCLOMETALLATED IMIDAZO (1,2-F)PHENANTHRIDINE AND DIIMIDAZO (1,2-A; 1', 2'-C)QUINAZOLINE LIGANDS AND ISOELECTRONIC AND BENZANNULATED ANALOGS THEREOF UNIVERSAL DISPLAY CORP (US) 2022-01-05 EP disclosed
EP-3569606-B1 METAL COMPLEXES OF CYCLOMETALLATED IMIDAZO (1,2-F)PHENANTHRIDINE AND DIIMIDAZO (1,2-A; 1', 2'-C)QUINAZOLINE LIGANDS AND ISOELECTRONIC AND BENZANNULATED ANALOGS THEREOF UNIVERSAL DISPLAY CORP (US) 2022-01-05 EP disclosed
US-10978649-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2021-04-13 US disclosed
US-20200350504-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2020-11-05 US disclosed
US-10749121-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2020-08-18 US disclosed
EP-3569606-A1 METAL COMPLEXES OF CYCLOMETALLATED IMIDAZO (1,2-F)PHENANTHRIDINE AND DIIMIDAZO (1,2-A; 1', 2'-C)QUINAZOLINE LIGANDS AND ISOELECTRONIC AND BENZANNULATED ANALOGS THEREOF Universal Display Corporation (US) 2019-11-20 EP disclosed
US-20190341563-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2019-11-07 US disclosed
US-10403831-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2019-09-03 US disclosed
WO-2008156879-A1 BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS UNIVERSAL DISPLAY CORPORATION (US) 2008-12-24 WO disclosed
WO-2008156879-A1 BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS UNIVERSAL DISPLAY CORPORATION (US) 2008-12-24 WO disclosed
US-20080297033-A1 BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS UNIVERSAL DISPLAY CORPORATION 2008-12-04 US disclosed
US-20080297033-A1 BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS UNIVERSAL DISPLAY CORPORATION 2008-12-04 US disclosed
US-20080297033-A1 BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS UNIVERSAL DISPLAY CORPORATION 2008-12-04 US disclosed
EP-1981898-A2 METAL COMPLEXES OF CYCLOMETALLATED IMIDAZOÝ1,2-f¨PHENANTHRIDINE AND DIIMIDAZOÝ1,2-A:1',2'-C¨QUINAZOLINE LIGANDS AND ISOELECTRONIC AND BENZANNULATED ANALOGS THEREOF Universal Display Corporation (US) 2008-10-22 EP disclosed
WO-2007095118-A2 METAL COMPLEXES OF CYCLOMETALLATED IMIDAZO[1,2-f]PHENANTHRIDINE AND DIIMIDAZO[1,2-A:1',2'-C]QUINAZOLINE LIGANDS AND ISOELECTRONIC AND BENZANNULATED ANALOGS THEREOF UNIVERSAL DISPLAY CORPORATION (US) 2007-08-23 WO disclosed
US-20070190359-A1 Metal complexes of cyclometallated imidazo[1,2-ƒ]phenanthridine and diimidazo[1,2-a:1',2'-c]quinazoline ligands and isoelectronic and benzannulated analogs thereof UNIVERSAL DISPLAY CORPORATION 2007-08-16 US disclosed
US-20070190359-A1 Metal complexes of cyclometallated imidazo[1,2-ƒ]phenanthridine and diimidazo[1,2-a:1',2'-c]quinazoline ligands and isoelectronic and benzannulated analogs thereof UNIVERSAL DISPLAY CORPORATION 2007-08-16 US disclosed
US-20070190359-A1 Metal complexes of cyclometallated imidazo[1,2-ƒ]phenanthridine and diimidazo[1,2-a:1',2'-c]quinazoline ligands and isoelectronic and benzannulated analogs thereof UNIVERSAL DISPLAY CORPORATION 2007-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190341563-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES LIG1, L1CAM, LIG3 GABRA1 498/4885GABRB1 1283/4885ALB 2937/4885
US-10978649-B2 Organic electroluminescent materials and devices NR2C2, NR2E3, NCOA2 GABRA1 163/4885GABRB1 179/4885ALB 4529/4885
US-20080297033-A1 BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS IK, CRY1, MAP1LC3C GABRA1 432/4885GABRB1 1628/4885ALB 3507/4885
US-10749121-B2 Organic electroluminescent materials and devices LIG1, L1CAM, LIG3 GABRA1 498/4885GABRB1 1283/4885ALB 2937/4885
US-10403831-B2 Organic electroluminescent materials and devices LIG1, L1CAM, LIG3 GABRA1 498/4885GABRB1 1283/4885ALB 2937/4885
US-20200350504-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES NR2C2, NR2E3, NCOA2 GABRA1 163/4885GABRB1 179/4885ALB 4529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.